Rogers, MirandaGill, DipenderAhlqvist, EmmaRobinson, Timothy M.Mariosa, DanielaJohansson, MattiasCortez Cardoso Penha, RicardoDossus, LaureGunter, Marc J.Moreno Aguado, VíctorDavey Smith, GeorgeMartin, Richard M.Yarmolinsky, James2023-09-042023-09-042023-06-012589-0042https://hdl.handle.net/2445/201727Preclinical and genetic studies suggest that impaired glucose-dependent insulino-tropic polypeptide receptor (GIPR) signaling worsens glycemic control. The rela-tionship between GIPR signaling and the risk of cancers influenced by impaired glucose homeostasis is unclear. We examined the association of a variant in GIPR, rs1800437 (E354Q), shown to impair long-term GIPR signaling and lower circulating glucose-dependent insulinotropic peptide concentrations, with risk of 6 cancers influenced by impaired glucose homeostasis (breast, colorectal, endometrial, lung, pancreatic, and renal) in up to 235,698 cases and 333,932 con-trols. Each copy of E354Q was associated with a higher risk of overall and luminal A-like breast cancer and this association was consistent in replication and colocal-ization analyses. E354Q was also associated with higher postprandial glucose concentrations but diminished insulin secretion and lower testosterone concen-trations. Our human genetics analysis suggests an adverse effect of the GIPR E354Q variant on breast cancer risk, supporting further evaluation of GIPR signaling in breast cancer prevention.19 p.application/pdfengcc by (c) Rogers, Miranda et al, 2023http://creativecommons.org/licenses/by/3.0/es/Genètica mèdicaCàncerMedical geneticsCancerinfo:eu-repo/semantics/article2023-08-18info:eu-repo/semantics/openAccess37250804